10-Q: Monopar Secures $91.9M, Advances Wilson Disease & Cancer Programs

Monopar Therapeutics significantly boosts its cash reserves by $91.9 million and reports clinical progress across its Wilson disease and radiopharmaceutical oncology pipeline.

Summary

• Monopar Therapeutics Inc. reported a substantial increase in cash and cash equivalents to $127.7 million as of September 30, 2025, up from $45.8 million at December 31, 2024.
• The company completed an underwritten public offering in September 2025, raising approximately $126.9 million in gross proceeds, and net proceeds of approximately $91.9 million after underwriting discounts, commissions, and a $35 million share repurchase from Tactic Pharma LLC.
• Management estimates that current funds are sufficient to meet obligations at least through December 31, 2027.
• Net loss for the nine months ended September 30, 2025, increased to $8.5 million, compared to $4.7 million for the same period in 2024, driven by increased research and development (R&D) and general and administrative (G&A) expenses.
• R&D expenses for the nine months ended September 30, 2025, were $5.96 million, a significant increase from $3.08 million in the prior year, primarily due to ALXN1840 manufacturing activities and R&D personnel expenses.
• G&A expenses also rose to $4.59 million for the nine months ended September 30, 2025, from $2.01 million in 2024, mainly due to increased Board compensation, G&A personnel expenses, legal fees, and insurance.
• The company is preparing to submit a New Drug Application (NDA) for ALXN1840 for Wilson disease to the FDA in early 2026, despite Alexion Pharmaceuticals Inc. previously terminating the program based on Phase 2 mechanistic trial results.
• Clinical trials for radiopharmaceutical programs are progressing, including a Phase 1 imaging and dosimetry trial for MNPR-101-Zr and a Phase 1a therapeutic trial for MNPR-101-Lu in advanced cancers, with FDA IND clearance for MNPR-101-Lu received on September 26, 2025.
• An Expanded Access Program (EAP) for MNPR-101-Zr and MNPR-101-Lu received FDA authorization on June 11, 2025, and is open for enrollment.
• Monopar filed a provisional patent application in October 2024 for new radiopharmaceutical compounds and linkers.

Sentiment

Score: 7

Explanation: The significant capital raise and extended cash runway are strong positives, providing stability for continued clinical development. Progress in both the Wilson disease and radiopharmaceutical programs, including FDA IND clearance, is encouraging. However, the increased net loss and the historical termination of ALXN1840 by Alexion introduce notable risks and uncertainties, preventing a higher score.

Positives

• Successfully completed an underwritten public offering and private placement, resulting in net proceeds of approximately $91.9 million after a share repurchase, significantly bolstering the company's cash position.
• Extended cash runway through at least December 31, 2027, providing critical funding for ongoing and future development programs.
• ALXN1840 for Wilson disease continues to show positive long-term efficacy and safety data in presentations at major medical conferences (EASL, ANA, AASLD), including sustained neurological and hepatic improvements and rapid copper balance improvement.
• Received FDA IND clearance for MNPR-101-Lu on September 26, 2025, allowing advancement of its therapeutic radiopharmaceutical program in advanced solid tumors.
• Progress in radiopharmaceutical clinical trials, with MNPR-101-Zr Phase 1 imaging trial showing positive early tumor-targeting data and MNPR-101-Lu Phase 1a therapeutic trial active and enrolling patients.
• FDA authorization for an Expanded Access Program (EAP) for MNPR-101-Zr and MNPR-101-Lu provides a pathway for patients with serious conditions to access investigational treatments.
• Filed a provisional patent application for new radiopharmaceutical compounds and linkers, strengthening intellectual property.

Negatives

• Net loss for the nine months ended September 30, 2025, increased significantly to $8.5 million from $4.7 million in the prior year, indicating higher operational burn.
• Operating expenses, including R&D and G&A, more than doubled for the nine months ended September 30, 2025, compared to the same period in 2024.
• Alexion Pharmaceuticals, Inc. previously terminated the ALXN1840 program in Wilson disease based on Phase 2 mechanistic trial results, which failed to demonstrate net-negative copper balance and reduced hepatic copper concentration, despite a successful Phase 3 primary endpoint, posing a potential regulatory challenge for Monopar's NDA.
• The company has an accumulated deficit of approximately $84.3 million as of September 30, 2025, and has not generated any revenue since inception, indicating continued reliance on external funding.

Risks

• The company is a clinical-stage biopharmaceutical company with a history of financial losses and expects to continue incurring significant losses, potentially never achieving profitability.
• Uncertainty regarding the ability to raise sufficient funds on acceptable terms to support continued clinical, regulatory, and commercial development of programs and to make contractual future milestone payments.
• Alexion's termination of the ALXN1840 program in Wilson disease, based on Phase 2 mechanistic trial results and regulatory discussions, introduces uncertainty regarding the outcome of Monopar's planned NDA submission.
• The regulatory approval process is lengthy, expensive, and uncertain, with the FDA potentially requiring additional nonclinical and/or clinical studies for ALXN1840 approval, which may not be fundable or yield sufficient results.
• The business is highly dependent on receiving marketing approvals from regulatory agencies, and failure to obtain approvals would severely harm the company.
• Clinical trials may not yield sufficiently conclusive results for regulatory approval.
• Potential delays or difficulties in patient enrollment in clinical trials could delay or prevent necessary regulatory approvals.
• Inability of the company or its licensees, development collaborators, or suppliers to manufacture products in sufficient quantities and/or at defined quality specifications, or to obtain regulatory approvals for manufacturing facilities.
• Reliance on qualified third parties to conduct manufacturing, non-clinical studies, and clinical trials, with risks if these parties fail to meet contractual duties or deadlines.
• Radiopharmaceutical technology is a relatively novel approach, which may create unpredictable challenges such as radioisotope availability, safety misconceptions, and low market uptake, potentially posing funding challenges.
• Geopolitical events (e.g., Russia-Ukraine war, Israel-Hamas war) may increase costs of clinical supplies, delay manufacturing, restrict radioisotope availability, and introduce financing difficulties.
• Market variables like inflation, labor rates, fuel, freight, and energy costs, as well as geopolitical events, may significantly increase operating and administrative expenses.
• Unstable market and economic conditions (e.g., volatility in financial markets, inflation, recession) may limit the ability to raise funds.
• U.S. political leadership developments may affect the economy, future laws, tariffs, regulations, or executive orders, potentially impacting healthcare, pharmaceuticals, and costs.
• Significant competition from other radiopharmaceutical, biotechnology, and pharmaceutical companies, many with greater capabilities and resources.
• Termination of third-party licenses would adversely affect rights to important compounds and/or technologies.
• Inability to obtain and preserve protection for intellectual property rights could allow competitors to develop and market competing drugs.
• Loss of key management leadership or scientific personnel, or inability to recruit qualified employees, could lead to significant program delays and increased costs.
• Uncertain future impacts of COVID-19 resurgence or other pandemics on business, financial condition, operating results, stock price, and ability to raise capital.

Future Outlook

Monopar Therapeutics plans to submit a New Drug Application (NDA) for ALXN1840 for Wilson disease to the FDA in early 2026. The company intends to continue conducting and concluding its first-in-human imaging and dosimetry clinical trial with MNPR-101-Zr, continue its first-in-human therapeutic clinical trial of MNPR-101-Lu, and advance its preclinical MNPR-101-Ac program into the clinic. Additionally, Monopar aims to invest in internal R&D projects to expand its radiopharmaceutical pipeline and continue to identify and potentially acquire or in-license additional product candidates, particularly those that leverage existing scientific and clinical data.

Management Comments

• Chandler D. Robinson, Chief Executive Officer, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact, and that the financial statements fairly present the financial condition, results of operations, and cash flows.
• Management believes that current funds will be sufficient at least through December 31, 2027, to advance ALXN1840, progress radiopharmaceutical programs, and invest in internal R&D.
• The management team leverages extensive experience in biopharmaceutical in-licensing, acquisitions, drug development, and commercialization to reduce risk and accelerate development.

Industry Context

Monopar Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on rare diseases (Wilson disease) and oncology radiopharmaceuticals. The radiopharmaceutical market is a relatively novel and evolving area, presenting both significant opportunities for precise cancer treatment and imaging, as well as challenges related to radioisotope supply, safety perceptions, and market adoption. The company's strategy of in-licensing late-stage assets like ALXN1840 and developing proprietary platforms like MNPR-101 aligns with industry trends of leveraging external innovation and specialized therapeutic modalities. The substantial capital raise reflects the high funding requirements typical for clinical-stage biotech companies advancing multiple programs.

Comparison to Industry Standards

• The company's accumulated deficit and continued operating losses are typical for a clinical-stage biopharmaceutical company that has not yet brought a product to market.
• The significant capital raise and extended cash runway to late 2027 position Monopar more favorably than many smaller biotechs that frequently face liquidity challenges, allowing for sustained development efforts without immediate financing pressure.
• The decision to pursue ALXN1840 despite Alexion's prior termination, based on Monopar's interpretation of Phase 3 data and ongoing regulatory discussions, highlights a high-risk, high-reward strategy common in rare disease drug development, where patient populations are small but unmet needs can be significant.
• The advancement of multiple radiopharmaceutical programs (MNPR-101-Zr, MNPR-101-Lu, MNPR-101-Ac) demonstrates a commitment to a cutting-edge and rapidly growing segment of oncology, competing with established players and emerging biotechs in the radiopharmaceutical space, such as Novartis (with Pluvicto) and other companies developing alphaand beta-emitting radioisotopes.

Corporate Governance

Legal Proceedings

• The company is not currently, and has never been, a party to any adverse material legal proceedings.

Related Party Transactions

• On September 24, 2025, the company repurchased 550,229 shares of its common stock from Tactic Pharma LLC for $35 million. Chandler D. Robinson, Monopar's Chief Executive Officer and a Board member, is a minority owner and non-controlling Managing Member of Tactic Pharma.

Stakeholder Impact

• **Shareholders:** Experienced significant dilution from the public offering but also benefited from a substantial increase in cash reserves, extending the company's operational runway. The share repurchase from a significant stockholder (Tactic Pharma) reduced their overall ownership percentage.
• **Employees:** Stock-based compensation increased, indicating continued incentives and potential for retention, particularly for R&D and G&A personnel.
• **Patients:** Progress in clinical trials for ALXN1840 (Wilson disease) and MNPR-101 (advanced cancers), along with the FDA-authorized Expanded Access Program, offers potential new treatment options for unmet medical needs.
• **Creditors:** The strengthened cash position and extended liquidity runway reduce immediate financial risk, improving the company's credit profile.
• **Regulatory Authorities:** The company is actively engaging with the FDA, including IND transfers and clearances, demonstrating adherence to regulatory pathways for drug development.

Next Steps

• Assemble a regulatory package and submit a New Drug Application (NDA) for ALXN1840 for Wilson disease to the FDA in early 2026.
• Continue to conduct and conclude the first-in-human imaging and dosimetry clinical trial with MNPR-101-Zr.
• Continue to conduct the first-in-human therapeutic clinical trial of MNPR-101-Lu.
• Advance the preclinical MNPR-101-Ac program into the clinic.
• Invest in internal research and development projects to expand the radiopharmaceutical pipeline.
• Identify and potentially acquire or in-license additional product candidates, focusing on novel and established targets that complement existing programs.

Key Dates

Recommendation

The company's significantly improved liquidity position, with a cash runway extended through late 2027, is a critical positive for a clinical-stage biopharmaceutical company. This provides a strong foundation for advancing its pipeline. Clinical programs for both Wilson disease (ALXN1840) and radiopharmaceuticals (MNPR-101) are showing progress and positive data, including FDA IND clearance for MNPR-101-Lu. However, the increased operating losses and the historical context of Alexion's termination of the ALXN1840 program (despite Monopar's continued pursuit) introduce substantial regulatory and commercial uncertainties. While the long-term potential exists, the inherent risks of drug development and the specific challenges with ALXN1840 warrant a cautious approach. Therefore, a 'hold' recommendation is appropriate, acknowledging the strengthened financial position and clinical progress, but also the significant execution risks ahead.

Keywords

Monopar Therapeutics, ALXN1840, Wilson disease, Radiopharmaceuticals, MNPR-101, Oncology, Clinical trials, Biotechnology, SEC filing, 10-Q, Capital raise, Drug development, Rare disease